L6, L8- Adrenergic Drug Overview Flashcards
list some disorders that are treated with adrenergic agonists or antagonists
- HTN
- HF, angina, arrhythmias
- asthma
- migraine
- anaphylactic reactions
describe the effect of epinephrine at low and high doses in skeletal muscle vasculature
Low: β2 more sensitive than α1, therefore physiological concentrations of epinephrine => vasodilation
High: α1/β2 activated, α1 predominates => vasoconstriction
describe the effects of epinephrine at low and high concentrations in terms of adrenergic activation
Low: mainly β1/β2 receptors are activated
High: α1 effects are more pronounced
list the general effects of epinephrine
- inc HR + contractile force => inc CO (inc myocardium O2 demand) (β1)
- inc renin release (β1)
-skin and viscera arterial vasoconstriction (α1)
- skeletal muscle BVs vasodilate (β2)
- bronchodilation (β2)
- inc liver glycogenolysis, inc α-cell glucagon release (β2)
-inc lipolysis (β1/β2)
describe the effects of epinephrine on BP at high doses (given IV)
Net inc in MAP:
- inc ventricular contraction (β1)
- inc HR (β1): may be opposed by baroreceptor reflex
- vasoconstriction (α1)
describe the effects of epinephrine on BP at low doses (given IV)
No net inc in MAP:
-inc ventricular contraction + inc HR (β1) => inc systolic pressure
-dec peripheral resistance, vasodilation (β2 more sensitive than α1) => dec diastolic pressure
[no change in MAP = no baroreceptor reflex]
describe the cardiovascular effects of NE
(Note- very little if any β2 activation)
Inc peripheral vascular resistance, SP, DP –> inc MAP + dec HR:
-peripheral vasoconstriction (α1)
-inc cardiac contractility (β1- CO is unchanged/decreased)
-inc MAP –> bradycardia via baroreceptor reflex
describe baroreceptor reflex in response to vasoconstriction / increased BP
- carotid sinus –> inc PSNS activity, dec SNS activity
- inc PSNS + dec SNS => dec HR
- dec SNS => dec cardiac force of contraction
describe baroreceptor reflex in response to vasodilation / decreased BP
- carotid sinus –> inc SNS activity, dec PSNS activity
- inc SNS + dec PSNS => inc HR
- inc SNS => inc cardiac force of contraction
the main cardiovascular effect of NE proceeding atropine administration is….
tachycardia
list in order of highest affinity the receptors DA binds to (in SNS)
D1 > β1 > α1
describe the cardiovascular effects of low dose dopamine
Mainly D1 in renal and other vascular beds are activated:
- vasodilation
- inc GFR, renal blood flow, Na excretion
describe the cardiovascular effects of intermediate dose dopamine
- more β1 receptors activated in heart inc CO (very little for β2)
- inc NE release from nerve terminals –> contributes to cardiac effects
- inc systolic BP, no change in diastolic => inc MAP, PVR unchanged
describe the cardiovascular effects of high dose dopamine
-more α1 receptors activated in vasculature => vasoconstriction –> inc BP
-TPR may be increased
(Note- these are the therapeutic or clinical doses used)
describe the effects of isoproterenol
(β agonist)
- β1: inc HR (potentiated by baroreceptor reflex), contractility, CO
- β2: skeletal muscle arteriole dilation –> dec PVR + bronchodilation
- dec diastolic, inc systolic pressure => dec MAP
dobutamine is a (1) type adrenergic drug that exhibits (2) type effect on the heart with (3) effects as the end result. It also has (4) effects on vasculature
1- β1 agonist
2- inotropic (mild chronotropic)
3- mild inc in HR and PVR
4- mild vasodilation
list the adverse effects of β2 agonists
- tremor, restlestness, apprehension, anxiety, tachycardia
- less likely in inhalation than with parenteral or oral therapy
describe the cardiovascular effects of phenylephrine
α1 vasoconstriction –> inc PVR –> inc diastolic/systolic BP + MAP => baroreceptor reflex leading to dec HR
clonidine works by activating on (1) receptors which leads to (2) in order to reduce (3); its adverse effects are (4)
1- pre-synaptic α2 receptors
2- reduce SNS outflow
3- reduce BP
4- lethargy, sedation, xerostomia
methyldopa is converted to (1) in order to act on (2) receptors, and results in (3) overall; its adverse effects are (4)
1- α-methylnorepinephrine (within noradrenerigic neurons)
2- central α2 receptors
3- dec BP
4- sedation, impaired mental concentration, xerostomia
what is the general mechanism of adrenergic releasing agents
inc in NE release from presynaptic terminals –> potentiates effects of endogenous NE
(1) is commonly found in fermented foods like cheese and wine (Chianti). It is oxidized by (2), therefore consumption of (1) is avoided in (3) patients as it can result in (4)
1- tyramine
2- MAO
3- MAOI patients (anti-depressants)
4- precipitate serious vasopressor episodes
describe the general mechanism of mixed-acting adrenergic agonists
- induces NE release
- activates adrenergic receptors
the general mechanism of α-adrenergic blockers is…
- SNS control of vasculature mainly due to α1
- blockade of α1 => reduces sympathetic tone (vasodilation) => dec PVR, BP